Prostate Cancer - Results from #28680

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with Docetaxel-treated castration-resistant prostate cancer - Abstract March 1, 2010

Significant and sustained antitumor activity in post-Docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate - Abstract March 1, 2010

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer - Abstract February 8, 2010

Does every prostate cancer need active intervention? - Multimedia Presentation October 29, 2009

A feasibility study of novel ultrasonic tissue characterization for prostate-cancer diagnosis: 2D spectrum analysis of in vivo data with histology as gold standard - Abstract October 12, 2009

ASCO 2009 - Phase II Multicenter Study of Chemotherapy-Naive Castration-Resistant Prostate Cancer (CRPC) not Exposed to Ketoconazole, Treated with Abiraterone Acetate (AA) Plus Prednisone - Session Highlights June 1, 2009

ASCO 2009 - A Multicenter Phase II Study of Abiraterone Acetate (AA) in Docetaxel Pretreated Castration-Resistant Prostate Cancer (CRPC) Patients - Session Highlights June 1, 2009

ASCO 2009 - Circulating Tumor Cells (CTC) in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC) Receiving Abiraterone Acetate (AA) after Failure of Docetaxel-Based Chemotherapy - Session Highlights June 1, 2009

Working patterns and perceived contribution of prostate cancer clinical nurse specialists: A mixed method investigation - Abstract April 20, 2009

The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer - Abstract December 12, 2008

Is Abiraterone Acetate Well Tolerated and Effective in the Treatment of Castration-Resistant Prostate Cancer? - Abstract November 7, 2008

Metabolic and Cardiovascular Effects of Androgen Deprivation Therapy - Abstract September 8, 2008

ASCO 2008 Annual Meeting - Updated Analysis of a Phase II Study Using Sorafenib (S) for Metastatic Castrate-Resistant Prostate Cancer (mCRPC) August 22, 2008

ASCO 2008 Annual Meeting - Phase II Trial of Thalidomide (T), Bevacizumab (Bv), and Docetaxel (Doc) in Patients (pts) with Metastatic Castration-Refractory Prostate Cancer (mCRPC) August 21, 2008

ASCO 2008 Annual Meeting - Phase I Trial of Ipilimumab (IPI) Alone and in Combination with Radiotherapy (XRT) in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) August 19, 2008

ASCO 2008 Annual Meeting - Identification of an Androgen Withdrawal Responsive Phenotype in Castrate Resistant Prostate Cancer (CRPC) Patients (pts) Treated with Abiraterone Acetate (AA) August 13, 2008

ASCO 2008 Annual Meeting - Crossover Pharmacokinetics (PK) Study to Assess Oral Administration of Abiraterone Acetate Capsule and Tablet Formulations in Fasted and Fed States in Patients with Prostate Cancer August 13, 2008

ASCO 2008 Annual Meeting - Anti-Tumor Activity of Abiraterone Acetate (AA), a CYP17 Inhibitor of Androgen Synthesis, in Chemotherapy Naive and Docetaxel Pre-Treated Castration Resistant Prostate Cancer (CRPC) August 13, 2008

ASCO 2008 Annual Meeting - Abiraterone Acetate and Prednisone in Patients (Pts) with Progressive Metastatic Castration Resistant Prostate Cancer (CRPC) After Failure of Docetaxel-Based Chemotherapy August 13, 2008

The influence of developmental life stage on quality of life in survivors of prostate cancer and their partners - Abstract July 1, 2008

Page 1435 of 1436